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To combat the threat to public health of antimicrobial resistance, there is a need for
faster, more portable diagnostic tools to aid in antibiotic selection. Current methods for
determining antimicrobial resistance of pathogens in clinical samples take days to result
and require high levels of user input. Microfluidics offers many potential benefits, reducing
time to result, user input, and allowing point of care testing. This review focuses on the
challenges of developing functional or phenotypicmicrofluidic antimicrobial susceptibility
tests; such methods complement other vital tools such as nucleic acid detection. Some
of the most important challenges identified here are not unique to microfluidics but
apply to most antimicrobial susceptibility testing innovations and relate to the nature
of the sample being tested. For many high priority samples, mixtures of bacteria,
highly variable target cell density, and the sample matrix can all affect measurements,
and miniaturization can create sensitivity problems if target bacteria are dilute. Recent
advances including smartphone capability, new sensors, microscopy, and a resurgence
in paper microfluidics offer important opportunities for microfluidic engineering to simplify
functional and phenotypic antimicrobial susceptibility testing. But the complexity of most
clinical samples remains one of the biggest barriers to rapid uptake of microfluidics for
antimicrobial resistance testing.
Keywords: microfluidics, antimicrobial resistance, antimicrobial susceptibility tests, smartphone, microbiology
BACKGROUND: WHY ARE ANTIBIOTIC SUSCEPTIBILITY TESTS
IMPORTANT AND WHAT ARE THE LIMITATIONS OF CURRENT
METHODS?
Many infectious diseases are caused by microorganisms that can be effectively treated using
antibiotics. However, antimicrobial resistance (AMR) remains a global threat as pathogens become
drug resistant, with estimates of 10 million deaths caused by AMR annually by 2050 (Tagliabue and
Rappuoli, 2018). One key priority identified by theWorld Health Organization (WHO) action plan
to tackle AMR is increased testing and surveillance (Mendelson and Matsoso, 2015). Laboratory
tests used to determine the antimicrobial sensitivity of these organisms are called antimicrobial
susceptibility tests (AST). Traditional AST include broth microdilution, to determine minimum
inhibitory concentration (MIC), and disc diffusion on agar. Both methods involve the initial
isolation of a bacterial colony from a clinical sample after overnight incubation on solid medium.
For broth microdilution, this monomicrobial cell suspension is grown in a microtitre plate in
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2-fold dilutions of target antibiotics. The MIC is described
as the lowest concentration of antibiotic for which bacterial
growth is not seen, and growth is usually measured by light
scattering or absorbance. For disc diffusion assays a lawn of
the isolated bacteria is plated onto an agar plate and filter
discs containing a fixed concentration of antibiotic are placed,
allowing antibiotic to diffuse into the solid medium, and the
size of the zone of inhibition is measured after overnight
growth. These methods have been used for over 50 years and
are used both for surveillance (to identify common resistance
and inform empirical treatment guidelines) and diagnostics (to
select effective treatments for bacterial infections) but are not
without their challenges. For example, these methods require
multiple rounds of culturing the sample, isolating colonies and
growth before and during testing. Time to result is more than
48 h, delivering results after the start of treatment by empirical
prescription of antibiotics. Evidence has suggested that up to
one fifth of antibiotics prescribed in the UK from 2013–15 were
inappropriate (Smieszek et al., 2018). One such way to reduce
this figure is to have better diagnostic tools to identify AMR in
infections prior to start of treatment, to reduce the inappropriate
or ineffective use of antibiotics.
Microfluidic technologies have the potential to be faster
and smaller than traditional microbiology phenotypic tests that
identify bacteria and determine antimicrobial susceptibility. A
number of preliminary microfluidic devices have demonstrated
that time to result could be reduced to same day predictions.
There are several strategies for the detection of bacteria and
bacterial resistance profiles (Figure 1). This review focusses on
FIGURE 1 | Antimicrobial susceptibility tests. Tests can be split into phenotypic or genotypic tests with traditional AST relying on bacterial growth. Phenotypic
microfluidics test times based on commercially available Accelerate PhenoTestTM BC Kit. Genotypic tests are typically faster than phenotypic tests and are more
suited to bacterial identification and the identification of genes or enzymes that confer antibiotic susceptibility. Created with BioRender.com.
the challenges of implementing rapid, miniaturized functional or
phenotypicmeasurements of antimicrobial susceptibility.
Current Conventional AST Measurements
Traditional AST measurements are dominated by broth
microdilution and disc diffusion. While these are time
consuming and labor intensive, they are built on decades
of refining and standardizing the measurement of bacterial
susceptibility, increasing reproducibility across labs. The
European Committee on Antimicrobial Susceptibility testing
(EUCAST) provides detailed guidance on correct media
preparation to interpretation of results. For broth microdilution,
results are only valid if there is clear growth in the positive
control (i.e., no antibiotic), the sample is of a pure culture and
is inoculated at or near to 5 × 105 CFU/mL. Variation from
these exact conditions can significantly affect the MIC measured
by these measures and despite standardized approaches, high
variation between labs has been recorded (Conville et al., 2012;
Espinel-Ingroff et al., 2013; Kavanagh et al., 2019).
Some innovations have accelerated the time to result for
conventional methods. For example, the Clinical and Laboratory
Standards Institute (CLSI) have identified that direct disc
diffusion may be used for some clinical isolates such as blood.
Positive blood culture samples are typically monomicrobial as
blood is sterile apart from the pathogen (Chandrasekaran et al.,
2018). The main variation from gold standard methodology is
variation in the inoculum number. Categorical agreement for
20 isolates ranged from 87.8 to 92.2% depending on the media
used. Earlier read times were also evaluated, however using both
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traditional method and direct disc diffusion lead to > 20% of
plates being too difficult to read due to light growth at 6 h. Direct
testing was found to have the best readability at 7.6 × 1 07-5 ×
108 CFU/mL, indicating that a wider range of bacterial inoculums
may be able to be used for categorical identification, but not MIC.
While this increases the time to result by around 24 h this method
does not improve upon standard ASTmethodology but adapts it.
The Need for Faster Time to Result
TheWHO has identified a lack of near-patient testing of bacterial
identification and AST, such that antibiotics cannot be prescribed
based on evidence, as a gap in existing diagnostics. This is
a particular challenge within the context of sepsis, multidrug
resistant gonorrhoeae, and distinguishing between bacterial and
non-bacterial infections (World Health Organization, 2019).
There is no “easy to use” platform for testing samples including
blood, urine, stool or respiratory specimens without first
culturing the organisms.
Depending on the type of infection, healthcare systems
have different requirements for testing. There are a number
of bacterial infections for which delaying treatment for 4–6 h
does not impact patient outcome, (Naucler et al., 2020) but
it would lead to increased workload by either withholding
prescriptions or changing prescription based on results. For
example, suspected urinary tract infections (UTI) are usually
presented in a primary care setting. Because point of care (POC)
testing to determine resistance profiles are not readily available,
antibiotics are prescribed empirically. Studies using currently
available POC tests have received mixed results depending on
how they are used. One study considered the use of Flexicult R©
SSI urinary kits for bacterial identification and determining
antimicrobial resistance in primary care settings in the UK. This
test uses traditional agar techniques to grow bacteria directly
from urine samples and can be used as a POC test without
significant investment (37◦C incubator). However, the test still
requires overnight incubation. The agar contains chromogenic
dyes allowing approximate bacterial identification. Portions of
the plate contain antibiotics to determine resistant profiles. This
study found no difference in patient recovery, UTI recurrence
or hospitalization when managed with standard care or with a
Flexicult R© test (Butler et al., 2018). Comparing the gold standard
and Flexicult R© test identified a good agreement in resistance
profiles, indicating the technique was technically accurate even
if no direct patient benefit was found. Although these tests are
unlikely to improve patient recovery or hospitalization of patients
presenting at primary care with uncomplicated infections, they
may still be useful in improving surveillance and reducing sample
load for central microbiology labs. A similar study was conducted
in Denmark using Flexicult R© SSI urinary kit and Flexicult R© ID
in a general practice for women presenting with UTI symptoms.
Similarly there was no improvement in prescription and patient
outcome when using these tests however, resistance levels in this
area were low and the biggest patient benefit would be expected
where higher frequency of resistant bacteria are present, or where
empirical selection guidelines are incomplete (Holm et al., 2017).
Automated systems have been implemented in secondary care to
decrease the hands-on user time. These allow higher throughput
but are not used as a point-of-care decision making tool. Many
of these involve simple inoculation systems using 96 well plates
preloaded with antibiotic solutions, or combined incubation with
analysis systems to monitor growth. The Mast Uri R© dot (Mast
Group Ltd) is an automated inoculator that transfers multiple
urine samples to plates containing pre-loaded media allowing
for AST and bacterial identification. While the test still requires
18–24 h incubation it decreases user time as liquid handling and
analysis are automated.
Beyond UTI, there are other infections such as sepsis where
antibiotics cannot be withheld and time to treatment severely
impacts patient outcome. These require sampling of different
biological matrices with different challenges: for sepsis, a major
problem is the very low bacterial concentration in blood (<50
CFU/mL) (Opota et al., 2015; Stranieri et al., 2018) making
culture diagnosis difficult, necessitating high sample volume
(recommended sample volume for sepsis diagnosis is between 10
and 30mL Bouza et al., 2007) and long incubation times.
For phenotypic AST, there are alternative ways to measure
bacterial growth. Instead of direct detection of bacteria by
light scattering (e.g., absorbance in microplates), colorimetric
or fluorogenic metabolic dyes can be used to detect growth at
earlier timepoints before cell density is high enough detectable
light scattering. Furthermore, microscopy can be used to examine
cell growth directly, making it possible to measure cell growth
even faster.
While growth-based detection tests require long incubation
times, there are other important tools to detect AMR (Figure 1)
many of which can be faster. Nucleic acid-based detection is fast
but cannot directly detect functional resistance—instead, known
resistance genes are detected. Likewise, some mass spectrometry
microbiology methods have extended beyond bacterial species
identification into detecting mass fingerprints of resistance.
Finally, many resistance mechanisms are enzymatic (e.g., beta-
lactamase) and can be detected with colorimetric or fluorogenic
substrates. These methods share the same limitation, that not all
resistance genes, enzymes or profiles for pathogens are known
and the presence of a known resistant gene or enzyme does not
always translate to resistant bacterial phenotype (let alone clinical
treatment outcomes), and so functional phenotypic methods
remain essential.
TECHNICAL CHALLENGES TO
PHENOTYPIC AST INNOVATION RELATE
TO SAMPLE COMPOSITION
There are many technical difficulties inminiaturizing or speeding
up these universally accepted gold standard conventional tests:
we focus on several specific technical challenges related to the
sample in the following sections. Phenotypic AST methods are
constrained fundamentally by the measurement of bacterial
cell growth, with or without antibiotics. Different infections
are associated with different bacteria with distinct growth
rates and resistance profiles. This leads to a need for many
distinct protocols. For a diagnostic test, either a flexible
platform is required, or tests have to be designed for a very
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specific and narrow use case. When considering UTI tests,
it is unlikely that one single test could be developed that
is suitable for UTI diagnosis and AMR identification in all
clinical presentations (uncomplicated v complicated, primary v
secondary v community care). Themost common causative agent
for UTI is uropathogenic E. coli (UPEC) with up to 90% of
infections caused by Gram-negative bacteria (Kline and Lewis,
2016). But polymicrobial infections are more likely to occur
in complicated UTI, such as immunocompromised individuals,
those with catherization, and the elderly (Kline and Lewis,
2016). Therefore, a novel AST for uncomplicated UTI may be
much easier to develop than for complicated UTI; yet the latter
may place a higher burden of morbidity and mortality than
uncomplicated UTI that often resolves without treatment.
Alongside technical barriers, the field is also highly regulated
and has clinical conventions that can be challenging and
expensive to align with when developing new technology. Over
many decades, overarching groups such as EUCAST have
identified specific and reproducible methods for determining
the AST conditions for many organisms that have known
clinical implications. Any new device entering the market
may need to demonstrate the same susceptibility profiles as
current protocols approved by regulators. Aligning the results
of novel microfluidic tests with the outputs of “gold standard”
conventional methods such as disc diffusion that are widely
familiar to clinicians and public health systems may require
expensive wide-scale clinical trials. Innovative devices can use
diversemeasurements that can be difficult to align with inhibition
zone diameters. The most directly comparable results should
be the more quantitative MIC that are typically measured by
broth microdilution, as these are designed to be directly linked
to growth in clinically significant concentrations of antibiotic
related to therapeutic levels achieved in patients. However,
many devices use single concentration breakpoints to identify
susceptibility profiles of multiple antibiotics; it becomes critical
to ensure these breakpoint concentrations are aligned to clinically
accepted values.
Influence of Sample Matrix on Assays
The first step in using gold standard methods of AST is the
overnight culture and isolation of bacteria from the sample.
Using a sample directly for AST tests without plating and
colony isolation immediately reduces the time to result by
18–24 h, cuts labor in picking colonies, and simplifies sample
preparation. Together, direct sample testing is an attractive
target and represents a “holy grail” for AST innovation.
However, biological samples are a complex mixture of molecules
many of which can significantly affect most biological analysis
methods. This is even more problematic as samples can vary
significantly between individuals. Samples can vary widely in
pH, nutrient composition, inoculum number, the number of
bacterial species (polymicrobial populations). They can also
contain varying levels of components that directly affect bacterial
growth, not only antimicrobial agents but also components that
can bind and inactivate the test antibiotic. Different patient
groups (catheterized, elderly, pregnant) and clinical history
(diet, medication, liquid intake before sampling, complicated
or uncomplicated infection etc.) can dramatically alter sample
matrix composition, making the composition of clinical samples
from patients often very different from healthy controls. Studies
looking at the growth of E. coli in different canine urine
composition found that increased urine concentration (higher
urine specific gravity) and higher pH levels showed decreased
levels of E. coli growth after 4 h (Thornton et al., 2018).
Urine components such as high levels of ascorbic acid can lead
to false negative results in dipstick tests (Mambatta et al., 2015).
Resazurin dye reduction is commonly used to detect metabolism
changing from blue to a pink color and from non-fluorescent to
a strong red fluorescence in the presence of metabolically active
bacteria. Resazurin has been incorporated in a number of AMR
microfluidic devices as well as traditional broth microdilution
methods (Boedicker et al., 2008; Elavarasan et al., 2013; Elshikh
et al., 2016; Hsieh et al., 2018; Kao et al., 2020). However, the
fluorescence of resorufin (the product of resazurin) is suspectable
to changes in pH. Furthermore, high ascorbic acid levels can
directly reduce resazurin in the absence of bacteria (Natto et al.,
2012). Urine pH also causes complications for many diagnostic
tests. Other chromogenic dyes used to detect bacterial growth
are pH dependent. Urine pH can range from pH 4–9 with more
alkaline pH associated with P. mirabilis in contrast to E. coli that
is associated with more acidic pH (Lai et al., 2019). Devices using
pH dependent dyes to monitor bacterial growth such as phenol
red (Cira et al., 2012; Reis et al., 2016; Lee et al., 2019) may
risk false positive results when using direct urine samples. The
application of the microfluidic test is an important factor when
choosing which indicator to use.
Agar based methods are good for direct sampling as this
dilutes the biological sample such as urine or blood with the solid
agar medium and can provide semi-quantitative measurement of
bacteria number. Flexicult R© Vet is used in veterinary surgeries
to determine UTI and AST on direct urine samples from cats
and dogs (Guardabassi et al., 2015). The sample is applied to the
plate and excess sample is removed. The plates do not provide
an MIC or zone of inhibition but can functionally identify which
bacteria grow or are inhibited by certain antibiotics which can aid
in prescription practices. Similar products using agar methods
for adaptable point of care testing include Diaslide, Uricult Trio,
and Dipstreak. But the benefits of solid media are offset by the
need for 18–24 h incubation, likely to be too slow in a primary
care setting to change current prescription practices. The ease
of use and availability does make it attractive for decentralized
surveillance schemes or in areas with high prevalence of resistant
bacteria or limited data to inform empirical antibiotic selection.
Polymicrobial Populations in Samples
Measuring bacterial growth directly in samples also raises the
challenge of potential polymicrobial populations. This can be
a pathogen plus harmless commensal organisms, or multiple
pathogens. Many tests do not distinguish between different
bacterial species because they are designed for single colony
isolates. Isolation of bacteria from a sample using agar plates
provides partial identification, either using chromogenic agar
to identify enzyme activity of different bacteria (Chaux et al.,
2002) or selective agar plus identification of colony morphology.
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Antibiotic treatment of polymicrobial infections is not fully
understood and treatment is made to target the most likely
organism (Lasa and Solano, 2018; Hebert et al., 2020). UTI
infections that involve two or more pathogens are much rarer
and analysis of mixed cultures is unclear. Public Health England
(PHE) determines a polymicrobial infection if each isolate is
105 CFU/mL but for analytical technology polymicrobial culture
should be considered to also include a single pathogen mixed
with commensal contaminants (Lough et al., 2019). There is a
lack of consensus as to the definition and role of polymicrobial
infections (Garg and Garg, 2017). This can make the need
for bacterial identification more or less important depending
on the infection. For UTIs polymicrobial infections are more
common in complicated infections making identification more
important than uncomplicated infections. It may be possible and
advantageous for infections with a high risk to be paired with
a rapid genotypic method to positively identify certain specific
target pathogenic bacteria that are associated with the most
patient harm.
Inoculum Effect
The initial inoculum cell density significantly affects MIC
determination as higher cell densities of susceptible organisms
may still showmeasurable growth in the presence of an inhibitory
concentration of antibiotic (Postek et al., 2018; Smith and
Kirby, 2018). This poses a significant challenge for direct testing
measurements as the initial concentration of bacteria in patient
samples is unknown. The inoculum effect (IE) refers to decreased
antibiotic efficacy on increasing bacterial numbers, and this effect
is more pronounced for measuring β-lactam susceptibility in β-
lactamase positive bacteria (Smith and Kirby, 2018). The Clinical
and Laboratory Standards Institute (CLSI) define the accepted
range of inoculum number between 2 × 105−8 × 105 CFU/mL.
Within this accepted inoculum range, when Enterobacteriaceae
were tested against meropenem, an 8-fold-difference in MIC was
observed (Smith and Kirby, 2018). Many potential diagnostic
tools for AMR use a single breakpoint concentration based on
EUCAST guidelines. EUCAST breakpoints are calculated from
MIC results and categorizes bacteria as susceptible, resistant or
intermediate for different antibiotics (Turnidge and Paterson,
2007). However, using an unknown inoculum concentration with
a fixed breakpoint antibiotic concentration may lead to errors in
susceptibility classification.
To control for this effect, some microfluidic devices include
an initial inoculum normalization step such as sample filtering
and dilutions. One example uses a pre-filtering step using syringe
filters to trap bacteria followed by resuspension, manual counting
and final dilution to EUCAST guidelines in growth media. While
this still requires a lot of user time, it reduces the overnight
culture step from 18 to 24 h to under 1 h and eliminates the
matrix effect. The bacteria are then grown in nanoliter volumes
using resazurin to detect bacterial growth in the presence of
antibiotics (Avesar et al., 2017). Using time-lapse fluorescence
microscopy, a different in growth curves is evident within 5.5 h.
This effect can also be overcome using microfluidic bacterial
counting techniques. Due to the miniaturized nature of
microfluidics, hundreds of conditions in microlitre-picolitre
FIGURE 2 | Device miniaturization limits the number of bacterial cells sampled.
Broth microdilution conditions from EUCAST are highlighted (EUCAST, 2003).
volumes can be run simultaneously in a single device. The multi-
RAPiD method takes serial dilutions of a sample loaded into
picochambers on chip in the presence of resazurin. Chambers
with bacteria present become fluorescent and using Poisson
distribution of the positive and negative chambers the initial
inoculum number can be determined. This method identified
good match between expected and counted positive chambers
for both E. coli and S. aureus (Hsieh et al., 2018). The same
outcome can be achieved using time-lapse imaging to build
growth curves with dilutions of starting inoculum number. The
time taken to reach a certain density or fluorescence intensity if
using a dye such as resazurin can be used to calculate the starting
inoculum (Travnickova et al., 2019). These countingmethods can
be incorporated with devices containing antibiotics to generate
AST or MIC results.
Analytical Sensitivity Following
Miniaturization
Miniaturization can reduce detection times and allow detection
of single cells. However, the cell concentration in some samples
may not be directly compatible with some microdevices because
the smaller the sample volume tested, the fewer cells will be
present and for example 103 CFU/mL is equivalent to only 1 CFU
per 1 microlitre of sample (Figure 2). The clinical range for UTI
diagnosis can range from ≥ 103 CFU/mL (Wilson and Gaido,
2004). A device that has an average of 1 CFU/device with a sample
volume of 1 µL can potentially detect 103 CFU/mL. Therefore,
it is important when engineering microdevices that the sample
volume tested will have sufficient bacterial cells at the clinically
relevant pathogen concentration for that infection. Within this
range, speed of detection can be increased by increasing sample
volume because for cell-growth based analysis the more bacteria
per device the faster the detection will be (Elshikh et al., 2016).
Microfluidics uses different approaches for miniaturization
of reactions including microdroplet formation (Idelevich et al.,
2018) and microchambers in fabricated devices (Avesar et al.,
2017; Azizi et al., 2018). The high surface to volume ratios
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TABLE 1 | Summary of phenotypic antimicrobial susceptibility tests.
Organisms Time to result Equipment used Approach References
GFP expressing E. coli DH5α <90min Fluorescence time-lapse
microscopy
Immobilized single cell
microscopy
Busche et al., 2019
GFP expressing E. coli, E. coli
(25922), S. aureus (29213
1–3 h Fluorescence time-lapse
microscopy
Microscopy of single cells in
chambers
Sun et al., 2019
Methicillin resistant S. aureus 16–24 h Visual color change Phenol red color change in
microchambers
Lee et al., 2019
E. coli 25922, K. pneumoniae
700603, S. aureus 29213, E.
faecalis 29212
0.25–0.5 h Bright-field time-lapse
microscopy
Growth in microdroplets Kang et al., 2019
YFP expressing E. coli 16 h Fluorescence microscopy Fluorescence intensity in
microdroplets
Postek et al., 2018
K. pneumoniae, E. coli < 5.5 h Fluorescence time-lapse
microscopy
Fluorescence intensity of
resazurin in microchambers
Avesar et al., 2017
E. coli, K. pneumoniae, E.
faecalis
1–3 h Fluorescence microscopy Fluorescence intensity of
resazurin in nanochambers
Azizi et al., 2018
E. coli < 4 h Phase contrast microscopy Motility of single cells Pitruzzello et al., 2019
E. coli 25922, S. aureus 29213,
P aeruginosa 27853
3–4 h Time-lapse microscopy Single cell growth immobilized
in agar
Choi et al., 2013
E. coli, K. pneumoniae, E.
cloacae, P. aeruginosa
2 h Fluorescence time-lapse
microscopy
Live/dead staining in single
cells trapped in microchannels
Kalashnikov et al.,
2017
E. coli, K. pneumoniae, S.
saprophyticus
0.5 h Time-lapse phase contrast
microscopy
Single cell growth in
microchannels
Baltekin et al., 2017
of microdevices have shown increased bacterial growth rates
compared to larger volume containers (10 µL v 13mL) such
as conical flasks (Chen et al., 2010). Studying the single cell
dynamics in these high surface area to volume devices allow faster
bacterial growth detection and therefore divergence of growth
curves in the presence of antibiotics will be able to determine
AST faster than bulk analysis relying on color change or OD
measurements. However, using smaller sample volumes also
reduces the number of bacteria in the devices. Some microfluidic
devices enhance bacterial detection by flowing larger sample
volumes through the device, capturing or trapping bacteria.
This can be achieved by immunocapture (Olanrewaju et al.,
2017; Pereiro et al., 2017; Alves and Reis, 2019) or by physical
boundaries (Pitruzzello et al., 2019).
The majority of these challenges are innate to the sample
tested rather than the methodology. The power of conventional
AST methods becomes clearer as they overcome these challenges
by apparently simple steps. For example, plating on agar
plates simultaneously removes the sample matrix, normalizes
cell number, and provides a monomicrobial culture, before
subsequent AST measurements. Rapid AST devices must either
bypass some of these steps or optimize the speed for each step.
NEW OPPORTUNITIES FOR
MICROFLUIDIC ANTIBIOTIC
SUSCEPTIBILITY TESTING
In spite of these challenges, recent developments around
microfluidic devices still offermassive potential for rapid portable
AST. Although some microfluidic devices still require laboratory
equipment to record results (e.g., fluorescence microscopy),
the increased availability of low-cost yet high performance
hardware—such as imaging devices and other optoelectronics—
makes developing microfluidic reader systems more affordable
(Needs et al., 2019). For instance, smartphone cameras combined
with imaging systems built from microscopy components make
POC fluorescence microscopy affordable (Chen et al., 2019). A
summary of recent phenotypic ASTmicrofluidic devices is shown
in Table 1.
Digital Microscopy
Digital microscopy is used to monitor changes in microfluidic
devices allowing imaging of single cells and monitoring color
or fluorescence changes in microchambers. Visually monitoring
motile bacteria such as E. coli using microscopy can be a
fast, but a user intensive method to identify urine bacteraemia.
After an incubation with different antibiotics, changes in cell
motility can be observed by eye. However, to increase throughput
and reproducibility automated analysis systems are required.
The majority of imaging-based detection methods of AST
use time-lapse imaging to identify the earliest divergence in
bacterial growth in reaction to different antibiotic exposure.
The Accelerate PhenoTest BC system received FDA approval
in 2017 for determining susceptibility in direct, positive
blood cultures within 7 h. This approved method uses time-
lapse imaging to follow bacterial growth in the presence of
antibiotics. For life threatening infections like blood infections
this advance is needed (Charnot-Katsikas et al., 2018). This
automated microscopic AST system illustrates the opportunities
for cell imaging.
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Microfluidics and digital microscopy can be combined
with computation to examine cell behavior in the presence
of antibiotics and to automate the analysis of antibiotic
susceptibility. One such device uses cup-shaped traps to monitor
the motility of single bacteria in the presence of different
antibiotics to identify susceptible strains within 2 h of exposure.
Phase contrast microscopy is used to monitor the individual
traps, and simple pixel intensity of the trap over time monitors
the motility of the bacteria (Pitruzzello et al., 2019). Other
devices use physical traps in conjunction with time lapse imaging
of single cells to monitor growth rather than motility. These
methods both accumulate bacteria from a sample and can
potentially replace the biological samplematrix (i.e., blood/urine)
with growth media. GFP expressing E. coli were trapped in
a channel-based device using hydrodynamic pressure. Parallel
channels linked by a nanogap allowed media exchange while
retaining cells along the edge of a single channel. The cells
were monitored every 30 s for 90min and cell chain length was
calculated for bacterial growth. Within 90min it was possible to
determine decreased growth in samples with media containing
200µg/mL kanamycin (Busche et al., 2019). Other trap designs
have used narrow channels (1.25 × 1.25 × 50µm) with a block
at one end that captures bacteria but maintains media flow. Using
phase contrast microscopy, the length of the channel occupied
with bacterial cells is calculated over time with either growth
media or in the presence of the antibiotic of choice. Using this
method, differences in growth time are detected within 30min
(Baltekin et al., 2017). Alternatives to physical traps include non-
specific binding to epoxide modified microchannels. Antibiotic
containing media can then be flowed through the channels
and live/dead cells were monitored by time-lapse microscopy
using phase contrast and SYTOX orange fluorescence marker
(Kalashnikov et al., 2017). This method was able to detect
susceptibility of Gram-negative bacteria within 60 min.
Additional approaches for bacterial immobilization in
microfluidic devices use agar based techniques. The microfluidic
agarose channel device flows liquid agarose and bacteria mix
into the device which solidifies. Antibiotic containing media
flows over the agarose layer and diffuses into the agarose/bacteria
mix. Bacterial growth is monitored using time-lapse imaging
and simple image analysis generating binary images the area
of bacteria growth in different channels can be calculated.
MIC and AST measurements can be detected within 4 h
(Choi et al., 2013).
Other single cell microscopy methods have combined
antibiotic gradient generators with bacteria cell culture
microchambers (Li et al., 2014b; Kim et al., 2015; Malmberg et al.,
2016). GFP-expressing E. coli were monitored by fluorescence
microscopy in cultivation chambers linked to an antibiotic
gradient device (Sun et al., 2019). The challenge of using this
method is to create a gradient of significant range for clinical
relevance as many gradient generators have a small range.
Broth microdilution methods use a 2-fold dilution series over
multiple dilutions (between 8 and 11 dilutions). This has been
demonstrated by using a gradient generator that provides 2-fold
dilutions over 7 channels (Kim et al., 2015).
Trap-based assays are less likely to be affected by sample
matrix or inoculum effect. The biological sample is flowed
through the device, the bacterial cells are captured/immobilized,
and the biological sample is replaced with nutrient media or
a constant flow of nutrient media. These techniques reduce
the effects of sample matrix on results and can rapidly detect
differentials in growth curves. They are also beneficial for samples
containing low levels of bacteria, such as blood infections as
higher volumes of sample can be passed through the devices.
Other methods, such as the agarose immobilization, do not allow
this and the bacteria measured are limited to the concentration
in the sample (Figure 2). The use of high-resolution fluorescence
microscopy and liquid handling machinery makes the usage of
these devices in a clinical setting unlikely since they require
high investment, user training and are unlikely to provide high
throughput testing capacity.
Smartphone Imaging
Smartphone use is being explored to enhance the usability
or analysis of POC testing. Many microfluidic and POC
tests are based on color changes which can be read by
the eye while with devices using micro- or picochambers
this can be challenging. Adding an imaging technique, can
allow devices to use automatic image analysis techniques or
provide quantitative or semi-quantitative data based on the
level of color or fluorescence intensity relating to the level
of biomarkers/growth. Recent advances in smartphone camera
systems and the combination of microscopy accessories can
be added to provide low-cost, portable microscopy systems
for bright-field, dark-field or fluorescence imaging (Hernández-
Neuta et al., 2019; Kheireddine et al., 2019). Smartphones have
also been used for complex analysis, increased usability through
patient interface for home testing or as a controller to drive
mechanical parts of microfluidic devices (Li et al., 2014a; Arango
et al., 2018; Temiz andDelamarche, 2018). Asmanymicrofluidics
devices are targeting POC tests, the readability of the results
is an important aspect of the overall system. When used as a
companion to microfluidic tests, smartphones are a prospective
low-cost clinical device. The images obtained can be analyzed
either by a custom app or processed manually.
One example of quantitative smartphone detection uses
immunocapture of E. coli in synthetic urine in microcapillaries.
This sandwich-based ELISA device uses fluorescent substrate
to detect captured bacteria. Using a simple LED and emission
filter setup, the fluorescent intensity of the microcapillaries
were detected using a smartphone camera with magnification
lens (Alves and Reis, 2019). This technique can determine
quantitative levels of bacteria in samples based on the
fluorescence production. Similarly, smartphone imaging has
been used for the immuno-detection of norovirus on a paper
microfluidic device. An external objective lens was added with
low-cost filters to detect fluorescent color changes (Chung et al.,
2019). The virus particles are captured by antibodies and particle
aggregation allows detection of single viral particles enabling an
extremely low limit of detection (LOD).
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One challenge when using smartphone camera detection
is that software embedded in the camera often automatically
adjusts the settings to deliver the “best” image for a consumer
user. Different images may be recorded with different exposure
settings. The camera settings may be fixed (Chung et al., 2019)
which can be challenging for different models and requires the
same model phone to be used with the specific test, limiting
potential users of the device, and making the use of personal
phones unlikely. Others include a color chart (Shen et al., 2012)
or reference sample of known fluorescence intensity so images
can be normalized during image analysis (Alves and Reis, 2019).
Bacteriophage Based Sensors
While antibiotic susceptibility tests dominate the diagnostic
need, developments are being made for the exploration of
bacteriophage treatments (Kutateladze and Adamia, 2010).
Bacteriophages have a different mechanism of action to
antibiotics. To fully take advantage of this method as a therapy,
complimentary systems for the rapid, low-cost, and reliable
detection of bacteria and determination of phage specificity
of an infectious organism are needed (Farooq et al., 2018).
Bacteriophage can also be engineered and used as tools for
bacterial detection. Bacteriophage can bind to bacteria with
high specificity potentially determining bacterial identification
and AST. This is already being put into practice in the
Smarticles (Roche) system. Bacteriophage reporters containing
luciferase genes are used to measure viable bacterial growth
measuring luminescence instead of turbidity. This method was
also used in conjunction with a model of blood infections.
Bacteria were separated from red blood cells using an
acoustophoretic microfluidic chip comprised of a single channel
with side and center inlets and outlets. The acoustophoresis
causes the red blood cells but not the bacteria to move to
the center channel and these are discarded via the center
outlet, while the bacterial cells are collected via the side
outlets. After bacteria collection a plate based luminescent
bacteriophage assay was performed (Dow et al., 2018), indicating
microfluidic devices can be used for the rapid purification
of bacteria from samples which can be adapted into an
AST workflow.
Paper Microfluidics
Microfluidic paper-based analytical devices (µPADs) are another
alternative for AMR detection. These are especially robust
for transport and storage and are typically made of low-cost
fabrication materials. They can be produced in a wide variety
of sizes, shapes and layers, and desired molecules can be easily
immobilized onto the paper, so the area of use and the target
cell can be diverse. Hydrophilic regions provide a spontaneous
microfluidic platform on µPADs reducing the need for complex
laboratory equipment such as pumps for liquid handling and
are therefore easy to use (one-step procedure). Colourimetric
methods are generally preferred for µPADs so the results can be
visualized by eye and do not require a dedicated reader (Martinez
et al., 2010; Hu et al., 2014).
A panel of four common antibiotics was tested against E.
coli using a laser-patterned paper based device. This device used
chromogenic agar as a nutrient source and to visualize the
bacteria when incubated at 37◦C overnight (He et al., 2020). A
filter paper layer then wicks the sample via capillary action and
distributes throughout the device without the need for additional
equipment. The final layer contains laser-patterned wells
containing different antibiotics. Another paper-based device was
used to measure β-lactam resistance in bacterial samples taken
from wastewater. This study used enzyme based β-lactamase
detection using the substrate nitrocefin for color change which
was captured by camera phone and was able to quantify the color
change in nitrocefin which was found to deliver the same LOD
as measured in a microtitre plate and plate reader. In another
paper-based system, antibiotic susceptibilities of E. coli and S.
typhimurium were examined using resazurin-based detection.
The system uses standard culture media in a reservoir and
requires 18 h incubation (Deiss et al., 2014). Paper microfluidics
may not provide a faster detection method, although researchers
are exploring direct sampling methods such as urine and
environmental samples for bacterial detection and AST. The
strength of these methods relies on portability, stability and
reduced need for laboratory equipment. Paper microfluidics offer
a cheap alternative at a cost of $ 0.20 (Boehle et al., 2017). They are
also more likely to be useful in samples that have a higher density
of bacteria and where a high volume of sample is available,
such as UTI.
CONCLUSION
Microfluidic techniques have many benefits for developing
portable, point-of-care diagnostics but there are significant
hurdles to overcome to develop rapid AST methods. Sample
matrix, inoculum effect and polymicrobial populations are still
challenges for conventional AST measurements. Whilst aPOC
phenotypic AST is a long way off, significant improvements
in the use of digital microscopy and smartphone imaging
and novel sensors are likely to increase the use of single
cell detection for rapid AST. An important factor in deciding
which microfluidic strategy to use is the type of infection
being targeted, and the clinical pathway it is expected to add
to or disrupt. For instance, devices which accumulate bacteria
may be useful for low concentration threshold infections such
as blood stream infections and would be expected to join a
secondary care setting whereas POC tests for uncomplicated
UTI would need minimal sample preparation and equipment.
The use of paper microfluidic in this area can provide
stable point of care testing. Not only are these devices
needed for the effective treatment of life-threatening infections
and effective treatment of disease, surveillance of antibiotic
resistance in health, agriculture, and environmental samples are
also needed to monitor and better tackle the emergence of
antimicrobial resistance.
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